The United Kingdom and the United States have announced a major trade agreement that will guarantee zero duties on British drug shipments being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on drugs through the public health system. This commitment ensures that import taxes on these key exports will remain at zero for a duration of three years.
This deal is in response to earlier statements to significantly raise tariffs on branded drug products, with potential rates discussed as high as one hundred percent.
"This agreement with the United Kingdom reinforces the worldwide climate for new treatments and establishes much-needed fairness to transatlantic drug exports," a statement declared.
Economic Importance
Medicines constitute one of the the United Kingdom's biggest export categories to the United States, which is easily the largest buyer for major UK drugmakers.
Export figures indicate that in the one-year period leading up to the third quarter, the UK shipped drugs valued at £11.1bn to the US. This figure represented 17.4% of British export trade in that span.
"This guarantee protects work, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," a government official stated.
Detailed NHS Changes
The pact entails several specific changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. Previously, rebates were more than 20%.
Broader Context
This agreement comes amid a long-running dispute between the sector and the ministers over spending levels and approval rates.
The disagreement were exacerbated by claims that American patients were charged a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its overall budget over the past decade.
